Compare · EIKN vs RVMD
EIKN vs RVMD
Side-by-side comparison of Eikon Therapeutics Inc. (EIKN) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EIKN and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $34.87B, about 135.8x EIKN ($256.8M).
- Over the past year, EIKN is down 67.8% and RVMD is up 127.3% - RVMD leads by 195.1 points.
- RVMD has been more active in the news (16 items in the past 4 weeks vs 7 for EIKN).
- RVMD has more recent analyst coverage (25 ratings vs 7 for EIKN).
- Company
- Eikon Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $256.8M
- $34.87B
- 1M return
- -42.03%
- -14.11%
- 1Y return
- -67.83%
- +127.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 7
- 16
- Recent ratings
- 7
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest EIKN
- Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
- SEC Form 10-Q filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
- Eikon Therapeutics to Participate in Multiple Investor Conferences in November
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Latest RVMD
- Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Officer Stephen Michael Kelsey exercised 27,160 shares at a strike of $18.56 and sold $4,559,209 worth of shares (27,160 units at $167.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Flavia Borellini exercised 2,500 shares at a strike of $37.54, increasing direct ownership by 10% to 28,715 units (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)